Intravitreal triamcinolone in recurrence of choroidal neovascularisation

• Published in: British journal of ophthalmology Vol. 86; no. 6; pp. 600 - 601
• Main Author: Penfold, P L
• Format: Journal Article
• Language: English
• Published: BMA House, Tavistock Square, London, WC1H 9JR BMJ Publishing Group Ltd 01-06-2002; BMJ Publishing Group LTD; Copyright 2002 British Journal of Ophthalmology
• Subjects: Anti-Inflammatory Agents - therapeutic use; Bioavailability; Chemotherapy, Adjuvant; Choroidal Neovascularization - drug therapy; Diabetic retinopathy; Hepatitis; Humans; Macular degeneration; Macular Degeneration - surgery; Permeability; Photodynamic therapy; Recurrence; Studies; Triamcinolone - therapeutic use
• ISSN: 0007-1161; 1468-2079
• DOI: 10.1136/bjo.86.6.600

The mode of action of triamcinolone on human choroidal endothelial cells remains to be completely defined The rationale for the use of glucocorticoids for the treatment of exudative macular degeneration has been derived from observations of both animal models 11- 14 and pathological specimens. 15 Evidence relating leucocytes and cytokines to the aetiology of choroidal new vessels and the role of retinal microglia in AMD has been reviewed previously. 16 In vitro studies indicate that triamcinolone has the capacity to modulate epithelial cell resistance and ICAM-1 expression.